We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Molecular Methods Differentiate Breast Cancers

By LabMedica International staff writers
Posted on 01 May 2012
Molecular technology has been used to the reclassify the manifestations of breast cancer into a multiplicity of different diseases. More...


By analyzing the DNA and ribonucleic acid (RNA) from breast cancer tumors, it is proposed that what are called breast cancer are in fact at least 10 different diseases, each with its own molecular fingerprint and pattern of weak spots.

In a landmark study that promises to revolutionize diagnosis and prognosis, and pave the way for individualized, tailored treatment, British and Canadian scientists uncovered crucial new information about breast cancer. The scientists analyzed the DNA and RNA of breast tumor samples from nearly 2,000 women who had been diagnosed between 5 and 10 years ago, and for whom information about the tumor characteristics had been meticulously recorded. The teams were from the Cambridge Research Institute (UK) and British Columbia Cancer Center (Vancouver, BC, Canada).

The team performed analyses on the DNA of the tumors--for instance, the map is now annotated with copy number changes and single letter variations or single-nucleotide polymorphism, for each tumor. The scientists also conducted a detailed analysis of the tumor RNA so they can tell which genes were active in each sample. Altogether, they did this for more than 30,000 types of RNA, each corresponding to the activity of a single gene.

The study revealed the relationship between breast cancer genes and known signaling pathways, the networks that control cell growth and division. This invaluable knowledge will help identify how variants of these genes cause cancer by interfering with cell processes. The team also discovered several previously unknown genes that drive breast cancer. Each of these is a potential target for new drugs, and should boost worldwide efforts to discover and develop new treatments.

Carlos Caldas, MD, professor of Cancer Medicine at Cambridge said, "We've drilled down into the fundamental detail of the biological causes of breast cancer, and we've moved from knowing what a breast tumor looks like under a microscope to pinpointing its molecular anatomy. Our results will pave the way for doctors in the future to diagnose the type of breast cancer a woman has, the types of drugs that will work, and those that won't, in a much more precise way than is currently possible." The study was published in the April 18, 2012, online issue of Nature.

Related Links:
Cambridge Research Institute
British Columbia Cancer Center


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.